simple obesity with asymptomatic hyperuricemia
Conditions
Interventions
Experimental:febuxostat tables
Sponsors
Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years old, male or female; 2. Serum uric acid (sUA) level =480 umol/L (8.0 mg/dl). If allopurinol or other serum uric acid lowering drugs, including probenecid tablets, benzbromarone tablets are used before selection, ten days after drug withdrawal Patients whose serum uric acid value is checked can meet the above criteria can be enrolled; 3. BMI = 28kg/m2, all subjects were fasting only after wearing fast-fitting underwear to measure height and weight. Measured three times and averaged, and calculated BMI according to the formula: body weight (Kg)/height 2 (m2); 4. Informed and willing to participate in the study, signed informed consent by himself or his legal guardian.
Exclusion criteria
Exclusion criteria: 1. Patients with gout or combined metabolic abnormalities of xanthine; 2. Creatinine clearance rate = 50 ml/min/1.73 m2, liver function (ALT, AST)> 2.5 times the upper limit of normal; 3. Diabetes, coronary heart disease, hypertension above class II(clinic SBP = 140mm Hg or DBP = 90mm Hg) and other diseases; 4. Combined use of theophylline drugs; 5. Combined use of other drugs to reduce urate: azathioprine, 6-mercaptopurine, aspirin (> 300 mg / d) and other salicylate drugs; 6. Oral contraceptives or hormone replacement therapy (prednisone dose >10 mg/d) within 3 months before the trial; 7. Plasma adrenocorticotropic hormone (ACTH) and cortisol abnormalities; 8. Severe cardiovascular and cerebrovascular diseases Endocrine system diseases Neuro-psycho-mental diseases; 9. Abuse history of alcohol or drug; 10. People with allergies who have allergies or contraindications to febuxostat; 11. Pregnancy and breastfeeding women, women of childbearing age who have not taken effective contraceptive measures, or those who plan to conceive during the trial, who have positive urine HCG test results before the trial; 12. Patients participated in clinical trials of other drugs within 1 month before enrollment; 13. Other investigators believe that the subject is not suitable for this test or cannot complete the test, giving the subject significant risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum urate;BMI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood biochemical tests;Immunoassay; | — |
Countries
China
Contacts
Public ContactChen Qiu
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed